Omeros Corporation (NASDAQ:OMER) Receives $40.33 Consensus Price Target from Brokerages

Omeros Corporation (NASDAQ:OMER) has earned an average rating of “Moderate Buy” from the five brokerages that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $40.3333.

A number of equities analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Omeros in a report on Thursday, January 22nd. HC Wainwright upped their price objective on shares of Omeros from $20.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. D. Boral Capital reissued a “buy” rating and set a $36.00 target price on shares of Omeros in a research note on Tuesday, January 27th. Finally, Wall Street Zen cut shares of Omeros from a “hold” rating to a “sell” rating in a report on Saturday, January 10th.

Insider Buying and Selling

In other Omeros news, CAO David J. Borges sold 30,000 shares of the company’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $12.31, for a total value of $369,300.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 12.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Omeros

Several large investors have recently made changes to their positions in OMER. UBS Group AG raised its position in Omeros by 213.5% during the fourth quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock valued at $38,180,000 after acquiring an additional 1,513,893 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Omeros by 19.9% during the 4th quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company’s stock valued at $68,929,000 after purchasing an additional 666,357 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Omeros by 1,201.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 416,153 shares of the biopharmaceutical company’s stock valued at $1,706,000 after purchasing an additional 384,168 shares during the last quarter. State Street Corp boosted its holdings in Omeros by 26.9% in the fourth quarter. State Street Corp now owns 1,573,526 shares of the biopharmaceutical company’s stock worth $27,025,000 after purchasing an additional 333,798 shares in the last quarter. Finally, Two Sigma Investments LP boosted its holdings in Omeros by 39.3% in the third quarter. Two Sigma Investments LP now owns 933,314 shares of the biopharmaceutical company’s stock worth $3,827,000 after purchasing an additional 263,095 shares in the last quarter. Institutional investors own 48.79% of the company’s stock.

Omeros Stock Down 5.0%

Shares of Omeros stock opened at $11.44 on Friday. The stock has a market cap of $811.10 million, a PE ratio of -5.66 and a beta of 2.45. Omeros has a 12 month low of $2.95 and a 12 month high of $17.65. The business has a fifty day simple moving average of $12.42 and a 200-day simple moving average of $8.50.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.